Advertisement

Click here for more guidelines.

 
 




CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2009; 54:2174-2179, doi:10.1016/j.jacc.2009.07.041
© 2009 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Go to related CVN interview
Right arrow View Related Go to related CVN interview Interview
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pascual-Figal, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pascual-Figal, D. A.
Related Collections
Right arrowRelated Article

CLINICAL RESEARCH: BIOMARKERS

Soluble ST2 for Predicting Sudden Cardiac Death in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction

Domingo A. Pascual-Figal, MD, PhD*,*, Jordi Ordoñez-Llanos, MD, PhD{dagger}, Pedro L. Tornel, PhD§, Rafael Vázquez, MD, PhD||, Teresa Puig, MD, PhD{ddagger}, Mariano Valdés, MD, PhD*, Juan Cinca, MD, PhD{ddagger}, Antoni Bayes de Luna, MD, PhD, Antoni Bayes-Genis, MD, PhD{ddagger} on behalf of the MUSIC Investigators

* Cardiology Service, Virgen de la Arrixaca Hospital and Department of Medicine, University of Murcia, Murcia, Spain
{dagger} Biochemistry Service, Sant Pau Hospital and Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Barcelona, Spain
{ddagger} Cardiology Service, Sant Pau Hospital, Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain
§ Biochemistry Service, Virgen de la Arrixaca Hospital, Murcia, Spain
|| Cardiology Service, Hospital Universitario Puerta del Mar, Cádiz, Spain
Institut Català de Ciències Cardiovasculars, Barcelona, Spain

Manuscript received June 9, 2009; accepted July 8, 2009.

* Reprint requests and correspondence: Dr. Domingo A. Pascual-Figal, Heart Failure Unit, Cardiology Department, University Hospital Virgen de la Arrixaca Ctra Madrid-Cartagena s/n, 30120 Murcia, Spain (Email: dapascual{at}servicam.com).

Objectives: We studied whether the measurement of the soluble form of ST2 (sST2), an interleukin-1 receptor family member, could identify heart failure (HF) patients at risk of sudden cardiac death (SCD).

Background: The prediction of SCD remains an important challenge in patients with mild-to-moderate chronic HF. Concentrations of sST2 have been found increased and related to worse long-term outcomes in patients with acute HF. Whether sST2 has a prognostic role in SCD is unknown.

Methods: A nested case-control study was performed on 36 cases of SCD and 63 control patients (matched for age, sex, and left ventricular ejection fraction) obtained from the MUSIC (MUerte Súbita en Insuficiencia Cardíaca) registry, a 3-year multicenter registry of ambulatory HF patients (New York Heart Association functional class II to III, left ventricular ejection fraction ≤45%). Demographic, clinical, echocardiographic, electrical, and biochemical data were collected at enrollment.

Results: Concentrations of sST2 were greater among decedents (0.23 ng/ml [interquartile range 0.16 to 0.43 ng/ml] vs. 0.12 ng/ml [interquartile range 0.06 to 0.23 ng/ml], p = 0.001) and were predictive of experiencing SCD (+0.1 ng/ml, odds ratio: 1.39, 95% confidence interval: 1.09 to 1.78, p = 0.006). On the basis of a combined biomarker status, only 4% of patients experienced SCD for neither sST2 nor N-terminal pro–B-type natriuretic peptide (NT-proBNP) above receiver-operator characteristic-derived cut-off points (0.15 ng/ml and 2,000 ng/l, respectively), 34% for either biomarker above, and 71% for both biomarkers above (p < 0.001 for trend). This combined variable added incremental prognostic value to the multivariable regression model (p < 0.001).

Conclusions: Elevated sST2 concentrations are predictive of SCD in patients with chronic HF and provide complementary information to NT-proBNP levels. A combined biomarker approach may have an impact on clinical decision-making.

Key Words: soluble ST2 • sudden cardiac death • chronic heart failure • B-type natriuretic peptide • biomarkers

Abbreviations and Acronyms
  BNP = B-type natriuretic peptide
  CI = confidence interval
  HF = heart failure
  IL = interleukin
  IQR = interquartile range
  LV = left ventricle/ventricular
  LVEF = left ventricular ejection fraction
  NT-proBNP = N-terminal pro–B-type natriuretic peptide
  OR = odds ratio
  ROC = receiver-operator characteristic
  SCD = sudden cardiac death
  sST2 = soluble ST2


Related Article

Inside This Issue
J. Am. Coll. Cardiol. 2009 54: A38. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Eur J Heart FailHome page
K. Broch, T. Ueland, S. H. Nymo, J. Kjekshus, J. Hulthe, P. Muntendam, J. J. McMurray, J. Wikstrand, J. G. Cleland, P. Aukrust, et al.
Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology
Eur J Heart Fail, February 2, 2012; (2012) hfs006v1.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. Deo and C. M. Albert
Epidemiology and Genetics of Sudden Cardiac Death
Circulation, January 31, 2012; 125(4): 620 - 637.
[Full Text] [PDF]


Home page
Eur J Heart FailHome page
A. Bayes-Genis, M. de Antonio, A. Galan, H. Sanz, A. Urrutia, R. Cabanes, L. Cano, B. Gonzalez, C. Diez, T. Pascual, et al.
Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure
Eur J Heart Fail, January 1, 2012; 14(1): 32 - 38.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
D. A. Pascual-Figal, I. P. Garrido, R. Blanco, A. Minguela, A. Lax, J. Ordonez-Llanos, A. Bayes-Genis, M. Valdes, S. A. Moore, and J. L. Januzzi
Soluble ST2 Is a Marker for Acute Cardiac Allograft Rejection
Ann. Thorac. Surg., December 1, 2011; 92(6): 2118 - 2124.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
P. A. Scott, P. A. Townsend, L. L. Ng, M. Zeb, S. Harris, P. J. Roderick, N. P. Curzen, and J. M. Morgan
Defining potential to benefit from implantable cardioverter defibrillator therapy: the role of biomarkers
Europace, October 1, 2011; 13(10): 1419 - 1427.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
D. A. Pascual-Figal, S. Manzano-Fernandez, M. Boronat, T. Casas, I. P. Garrido, J. C. Bonaque, F. Pastor-Perez, M. Valdes, and J. L. Januzzi
Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure
Eur J Heart Fail, July 1, 2011; 13(7): 718 - 725.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. T. Owens and M. Jessup
The Year in Heart Failure
J. Am. Coll. Cardiol., April 12, 2011; 57(15): 1573 - 1583.
[Full Text] [PDF]


Home page
Circ Heart FailHome page
B. Ky, B. French, K. McCloskey, J. E. Rame, E. McIntosh, P. Shahi, D. L. Dries, W. H. W. Tang, A. H. B. Wu, J. C. Fang, et al.
High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure
Circ Heart Fail, March 1, 2011; 4(2): 180 - 187.
[Abstract] [Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement